CRIS Current Research Information System

STEFANINI, BERNARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.502
NA - Nord America 1.509
EU - Europa 1.088
SA - Sud America 181
AF - Africa 109
OC - Oceania 2
Totale 6.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.432
VN - Vietnam 927
CN - Cina 885
SG - Singapore 761
IT - Italia 540
BD - Bangladesh 295
HK - Hong Kong 195
KR - Corea 161
BR - Brasile 126
NL - Olanda 107
DE - Germania 86
IN - India 75
FR - Francia 68
JP - Giappone 62
FI - Finlandia 60
GB - Regno Unito 36
CA - Canada 34
ZA - Sudafrica 34
IE - Irlanda 32
RU - Federazione Russa 30
SE - Svezia 30
AT - Austria 24
SC - Seychelles 23
MX - Messico 22
TH - Thailandia 22
PH - Filippine 21
AR - Argentina 20
TW - Taiwan 15
CH - Svizzera 13
PK - Pakistan 13
PL - Polonia 12
BG - Bulgaria 11
CI - Costa d'Avorio 11
ID - Indonesia 11
IQ - Iraq 11
TR - Turchia 11
CO - Colombia 9
MA - Marocco 9
EC - Ecuador 7
EG - Egitto 6
ES - Italia 6
MY - Malesia 6
UA - Ucraina 6
BE - Belgio 5
CL - Cile 5
RO - Romania 5
TG - Togo 5
VE - Venezuela 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DZ - Algeria 4
HN - Honduras 4
JM - Giamaica 4
LT - Lituania 4
NG - Nigeria 4
UZ - Uzbekistan 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
IL - Israele 3
KE - Kenya 3
LB - Libano 3
PY - Paraguay 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BF - Burkina Faso 2
CZ - Repubblica Ceca 2
JO - Giordania 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BT - Bhutan 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MF - Saint Martin 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
UG - Uganda 1
Totale 6.390
Salva come PNG Salva come JPEG
Città #
Singapore 505
Hefei 330
Ashburn 255
Hanoi 248
Ho Chi Minh City 245
San Jose 199
Hong Kong 170
Bologna 161
Seoul 143
New York 86
Santa Clara 83
Los Angeles 73
Council Bluffs 69
Beijing 64
Boardman 58
Tokyo 52
Da Nang 49
Dallas 48
Milan 46
Rome 44
Lauterbourg 42
Buffalo 36
Bengaluru 34
Johannesburg 33
Dublin 32
Haiphong 29
Helsinki 29
Lappeenranta 29
Frankfurt am Main 28
São Paulo 27
Amsterdam 25
Guangzhou 20
Naples 18
Nuremberg 17
Redondo Beach 17
Orem 16
Can Tho 15
Chicago 15
Tongling 14
Vienna 14
Falkenstein 13
Abidjan 11
Bern 11
Denver 11
Florence 11
Mexico City 11
Montreal 11
Ninh Bình 11
Shanghai 11
Sofia 11
Warsaw 11
Munich 10
Shenzhen 10
Stockholm 10
The Dalles 10
Toronto 10
Turin 10
Biên Hòa 9
Brooklyn 9
Lahore 9
Palermo 9
Vĩnh Long 9
Chandler 8
Ha Long 8
Hải Dương 8
Jakarta 8
Atlanta 7
Baghdad 7
Bangkok 7
Chennai 7
Modena 7
Phoenix 7
San Francisco 7
Thái Nguyên 7
Boston 6
Bắc Ninh 6
Charlotte 6
Genoa 6
Philadelphia 6
Quận Ba 6
Rimini 6
Seattle 6
Shenyang 6
St Petersburg 6
Vũng Tàu 6
Bucharest 5
Curitiba 5
Houston 5
Hưng Yên 5
Lomé 5
Nha Trang 5
Phú Thọ 5
Quận Một 5
Salt Lake City 5
Shijiazhuang 5
Tân Tiến 5
Venice 5
Verona 5
Ankara 4
Baku 4
Totale 3.873
Salva come PNG Salva come JPEG
Nome #
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 233
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 209
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 202
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 187
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 185
Association between anatomic variations of extrahepatic and intrahepatic bile ducts: Do look up! 171
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 163
TKIs in combination with immunotherapy for hepatocellular carcinoma 160
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 156
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 156
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 152
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 151
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 150
Advancements in immunotherapy for hepatocellular carcinoma 142
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 140
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease 138
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 121
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 112
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 112
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe 112
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 105
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 103
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 103
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 99
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 95
RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives 94
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 93
Artificial intelligence in Ultrasound: Pearls and pitfalls in 2024 92
Thinking outside the box: unconventional artificial intelligence algorithms in the detection and management of liver cirrhosis 90
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma 89
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 87
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement 86
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? 83
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 82
Liver Fat Quantification: When do We Need It? 80
Letter to the editor on the article Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement by Zhou and collaborators 79
Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review 78
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 78
Conversion to liver transplantation following atezolizumab-bevacizumab for HCC: the Bologna experience 77
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 76
Perirenal ultrasound abnormality: When to think at Xantogranulomatous Erdheim-Chester disease 75
HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients 74
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 72
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 72
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 72
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma 70
Ultrasound, the handyman serving our whole populations in the post COVID-19 pandemic 70
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib 69
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 66
Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease 65
OS-064 Integrating gut microbiota composition and machine learning to predict therapeutic response in hepatocellular carcinoma treated with Atezolizumab and Bevacizumab: exploratory analysis from the phase 3b AMETHISTA study 62
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials 57
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis? 53
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause? 50
Occupational toxicants in MASLD: Bias, complexity, and future directions 49
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 45
THU-402-YI Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in noncirrhotic MASLD patients 43
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 43
Ultrasound in clinical enviroments: Where are we standing? 43
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 38
THU-401 Liver stiffness and MACE development: an intricate relationship 37
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab 8
Totale 6.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.800
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.800
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 0 0 1 7 2 0 2 4
2022/2023130 2 9 5 4 6 8 5 10 36 3 20 22
2023/2024166 10 14 12 11 12 30 7 28 10 12 12 8
2024/20251.104 24 78 76 73 102 46 103 32 47 106 122 295
2025/20265.156 375 444 284 375 434 167 605 274 922 379 500 397
Totale 6.572